A DNA Vaccine against Chikungunya Virus Is Protective in Mice and Induces Neutralizing Antibodies in Mice and Nonhuman Primates
2011

A DNA Vaccine against Chikungunya Virus Is Protective in Mice and Induces Neutralizing Antibodies in Mice and Nonhuman Primates

Sample size: 30 publication 10 minutes Evidence: high

Author Information

Author(s): Mallilankaraman Karthik, Shedlock Devon J., Bao Huihui, Kawalekar Omkar U., Fagone Paolo, Ramanathan Aarthi A., Ferraro Bernadette, Stabenow Jennifer, Vijayachari Paluru, Sundaram Senthil G., Muruganandam Nagarajan, Sarangan Gopalsamy, Srikanth Padma, Khan Amir S., Lewis Mark G., Kim J. Joseph, Sardesai Niranjan Y., Muthumani Karuppiah, Weiner David B.

Primary Institution: University of Pennsylvania School of Medicine

Hypothesis

Can a synthetic DNA vaccine effectively induce protective immunity against Chikungunya virus in mice and nonhuman primates?

Conclusion

The study demonstrates that the DNA vaccine induces strong immune responses and provides protection against Chikungunya virus in both mice and nonhuman primates.

Supporting Evidence

  • Vaccination induced robust antigen-specific immune responses in mice.
  • Rhesus macaques showed neutralizing antibody responses similar to those in convalescent human sera.
  • The DNA vaccine construct was designed to express all three envelope proteins of the virus.
  • Immunized mice showed significantly lower viremia after viral challenge.
  • Histopathological evaluations indicated reduced tissue damage in vaccinated mice.
  • Neutralizing antibody titers in vaccinated monkeys were comparable to those in infected humans.
  • The study provides a potential model for future Chikungunya vaccine development.
  • High levels of neutralizing antibodies were associated with protection against the virus.

Takeaway

Scientists created a new vaccine to protect against a virus called Chikungunya, and it worked well in mice and monkeys.

Methodology

The study involved isolating a new Chikungunya virus strain, developing a DNA vaccine, and testing its efficacy in mice and rhesus macaques.

Potential Biases

Potential conflicts of interest due to funding from commercial entities involved in vaccine development.

Limitations

The study primarily focused on animal models, and further research is needed to confirm efficacy in humans.

Participant Demographics

The study included 30 patients from outbreak areas in India, all experiencing symptoms of Chikungunya.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pntd.0000928

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication